Is ImmunoGen, Inc. (IMGN) Stock a Sell after Daniel Junius’s Insider Trading?; Noble (NE) Shorts Up By 2.52%

Noble Corporation (NYSE:NE) had an increase of 2.52% in short interest. NE’s SI was 38.94 million shares in February as released by FINRA. Its up 2.52% from 37.98 million shares previously. With 7.95M avg volume, 5 days are for Noble Corporation (NYSE:NE)’s short sellers to cover NE’s short positions. The SI to Noble Corporation’s float is 17.1%. The stock decreased 0.64% or $0.025 during the last trading session, reaching $3.895. About 2.63 million shares traded. Noble Corporation plc (NYSE:NE) has declined 46.66% since February 14, 2017 and is downtrending. It has underperformed by 63.36% the S&P500.

According to a legal report that has been filled with the Washington-based Security and Exchange Commission on 14/02/2018, Daniel Junius, director of Immunogen Inc and an insider with a special knowledge about the firm, sold 46,667 shares of the firm for the total sum of $467,253 U.S Dollars which is based on an average stock price per share of $10.0. Daniel Junius now indirectly has ownership of 0 shares. He also directly has ownership of 196700 shares. In total he holds a stake of 0.15%.

Investors sentiment decreased to 1.16 in 2017 Q3. Its down 0.04, from 1.2 in 2017Q2. It turned negative, as 16 investors sold ImmunoGen, Inc. shares while 48 reduced holdings. 38 funds opened positions while 36 raised stakes. 87.70 million shares or 19.45% more from 73.42 million shares in 2017Q2 were reported. Gsa Cap Partners Ltd Liability Partnership holds 0.06% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 119,824 shares. Twin Focus Ptnrs Llc reported 113,216 shares. Kazazian Asset Limited Liability Corporation, New York-based fund reported 46,644 shares. Arrowstreet Capital Lp invested in 817,616 shares. Jfs Wealth Advsrs Llc holds 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 1,150 shares. Oppenheimer Asset Mngmt invested in 0% or 13,059 shares. Redmile Ltd Liability Company reported 3.04% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). State Board Of Administration Of Florida Retirement Systems accumulated 81,040 shares or 0% of the stock. 42,799 are held by Jane Street Group Inc Ltd Liability Corporation. Private Advisor Grp Ltd Liability Corporation has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Bnp Paribas Arbitrage invested 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). 58,000 are owned by Baxter Bros. Geode Capital Mgmt Lc holds 0% in ImmunoGen, Inc. (NASDAQ:IMGN) or 884,550 shares. Moreover, Price T Rowe Assocs Md has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 935,136 shares. Td Asset Inc has invested 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN).

The stock increased 1.53% or $0.15 during the last trading session, reaching $9.95. About 875,600 shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since February 14, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.

Analysts await ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings on February, 16. They expect $-0.07 EPS, up 82.05% or $0.32 from last year’s $-0.39 per share. After $-0.37 actual EPS reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts -81.08% EPS growth.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.32 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The company??s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen has $24 highest and $500 lowest target. $13.63’s average target is 36.98% above currents $9.95 stock price. Immunogen had 28 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, July 6. The company was maintained on Tuesday, August 29 by Leerink Swann. As per Monday, June 26, the company rating was maintained by Jefferies. The firm has “Hold” rating given on Tuesday, August 29 by Cantor Fitzgerald. Oppenheimer maintained it with “Outperform” rating and $24 target in Wednesday, July 29 report. The stock has “Buy” rating by Jefferies on Friday, September 8. The firm has “Buy” rating by Jefferies given on Friday, November 3. The firm has “Buy” rating given on Wednesday, August 30 by Canaccord Genuity. As per Monday, May 2, the company rating was maintained by Leerink Swann. Cowen & Co maintained the shares of IMGN in report on Tuesday, August 29 with “Hold” rating.

Since September 13, 2017, it had 0 insider buys, and 2 insider sales for $262,957 activity. The insider BARROWS CRAIG sold 37,050 shares worth $252,457. The insider Berkenblit Anna sold $10,500.

Noble Corporation plc operates as an offshore drilling contractor for the gas and oil industry worldwide. The company has market cap of $954.15 million. It owns and operates a fleet of mobile offshore drilling units. It currently has negative earnings. As of February 23, 2017, the firm operated a fleet of 28 offshore drilling units consisted of 14 drill ships, and semisubmersibles and 14 jack ups.

Among 34 analysts covering Noble Corp PLC (NYSE:NE), 9 have Buy rating, 8 Sell and 17 Hold. Therefore 26% are positive. Noble Corp PLC had 95 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Noble Corporation plc (NYSE:NE) earned “Sector Outperform” rating by Howard Weil on Friday, July 31. The rating was upgraded by Arctic Securities on Tuesday, January 3 to “Buy”. The stock has “Sell” rating by BMO Capital Markets on Tuesday, July 11. On Friday, August 25 the stock rating was upgraded by RBC Capital Markets to “Sector Perform”. The stock of Noble Corporation plc (NYSE:NE) has “Buy” rating given on Tuesday, January 19 by Societe Generale. The firm has “Neutral” rating given on Tuesday, March 15 by Susquehanna. The company was initiated on Tuesday, October 20 by Citigroup. The stock of Noble Corporation plc (NYSE:NE) has “Buy” rating given on Friday, January 8 by Societe Generale. The firm has “Accumulate” rating by Seaport Global given on Monday, March 14. The stock of Noble Corporation plc (NYSE:NE) earned “Buy” rating by Argus Research on Wednesday, September 23.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: